Nanopublication

< Home

ID

http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o> .
@prefix sub: <http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_10763> bl:category bl:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_10763>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00700>;
    rdfs:label "for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB00700> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "VPX3+yTpfORo6AeUODBGVsyvRsB+decUKsUS82MtIhthlmwdRaA0Q/KNe/78xinftMMV2P04HrX8SWlVpxoxVPGjWRiP/uAkuDIRG9zq7vBGi11Lm1ufVRvX+ZF25AUiJlfamWTG0WonXRXouZA7atV+o5Fty/2zQd53d4DX7jI=";
    npx:hasSignatureTarget this: .
  
  this: dc1:created "2021-06-12T15:36:15.751+02:00"^^xsd:dateTime;
    dc1:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}